DanielSBergerMD

PubMed

• 14 citations
  Liver Diseases During Pregnancy.
  Karen Ma, Daniel Berger, Nancy Reau> ;Clinics in Liver Disease. 2019 May 1
• 13 citations
  Patients with small and diminutive proximal hyperplastic polyps have higher rates of synchronous advanced neoplasia compared with patients without serrated lesions
  Thayer Hamoudah, Karen Ma, Marcus Juan L. Esteban, Waqas Hayat, Daniel Berger, Brett Mahon, Shriram Jakate, Joshua Melson> ;Gastrointestinal Endoscopy. 2018 Jun 1
• 7 citations
  Adenoma detection rate metrics in colorectal cancer surveillance colonoscopy
  Jamie M. Tjaden, Jessica Hause, Daniel Berger, Samantha K. Duveneck, Shriram Jakate, Bruce A. Orkin, Elizabeth L. Hubbard, Joshua Melson> ;Surgical Endoscopy. 2018 Jan 16
• 26 citations
  Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a...
  Pedro Cahn, Richard Kaplan, Paul E. Sax, Kathleen Squires, Jean-Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelyn Rojas, Mohammed Rassool, Mark Bloch, Li...> ;The Lancet. HIV. 2017 Nov 1
• Embryo quality but not pronuclear score is associated with clinical pregnancy following IVF.
  Berger, D. S.,Zapantis, A.,Merhi, Z.,Younger, J.,Polotsky, A. J.,Jindal, S. K.> ;J. Assist. Reprod. Genet.. 2014 Jan 07
• 243 citations
  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
  Peter Ruane, Edwin DeJesus, Daniel S Berger, Martin Markowitz, U. Fritz Bredeek, Christian Callebaut, Lijie Zhong, Srini Ramanathan, Martin S. Rhee, Marshall W. Fordyc...> ;Journal of Acquired Immune Deficiency Syndromes. 2013 Aug 1
• Leptin suppresses anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF.
  Merhi, Z.,Buyuk, E.,Berger, D. S.,Zapantis, A.,Israel, D. D.,Chua, S.,Jindal, S.> ;Hum. Reprod.. 2013 Jun
• 31 citations
  Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomize...
  Mark T. Nelson, Gerardo Amaya, Nathan Clumeck, Clovis Arns da Cunha, Dushyantha Jayaweera, Patrice Junod, Taisheng Li, Pablo Tebas, Marita Stevens, Annemie Buelens, Si...> ;The Journal of Antimicrobial Chemotherapy. 2012 Aug 1
• A new era in HCV treatment.
  Daniel S Berger> ;Positively Aware. 2011 May 1
• 200 citations
  Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
  Jeffrey L. Lennox, Edwin DeJesus, Daniel S Berger, Adriano Lazzarin, Richard B. Pollard, José Valdez Madruga, Jing Zhao, Hong Wan, Christopher L. Gilbert, Hedy Teppler...> ;Journal of Acquired Immune Deficiency Syndromes. 2010 Sep 1
• 3 citations
  Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir
  Richard Elion, Daniel S Berger, Gary Richmond, Michael Sension, Edwin DeJesus, Cimoch Pj, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2010 May 1
• 101 citations
  Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial.
  Andrew R. Zolopa, Daniel S Berger, Harry Lampiris, Lijie Zhong, Steven L. Chuck, Jeffrey Enejosa, Brian P. Kearney, Andrew K. Cheng> ;The Journal of Infectious Diseases. 2010 Mar 15
• 49 citations
  Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safet...
  Julian Falutz, Diane Potvin, Jean-Claude Mamputu, Hani Assaad, Monika Zoltowska, Sophie-Elise Michaud, Daniel S Berger, Michael Somero, Graeme Moyle, Stephen Brown, Cl...> ;Journal of Acquired Immune Deficiency Syndromes. 2010 Mar 1
• 239 citations
  Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 ...
  Joseph J. Eron, Benjamin Young, David A. Cooper, Mike Youle, Edwin DeJesus, Jaime Andrade-Villanueva, Cassy Workman, Roberto Zajdenverg, Gerd Fätkenheuer, Daniel S Ber...> ;Lancet. 2010 Jan 30
• 495 citations
  Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind rando...
  Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin, Richard B. Pollard, José Valdez Madruga, Daniel S Berger, Jing Zhao, Xia Xu, Angela Williams-Diaz, Anthony Rodgers,...> ;Lancet. 2009 Sep 5
• We mourn our great loss. Paying homage to Martin Delaney. 1945-2009.
  Daniel S Berger> ;Positively Aware. 2009 Mar 1
• 12 citations
  Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC stu...
  P. Yeni, A. Lamarca, Daniel S Berger, Cimoch Pj, Adriano Lazzarin, P. Salvato, Fiona Smaill, E. Teofilo, Sam J. Madison, W. G. Nichols, K. K. Adkison, T. Bonny, J. Mil...> ;HIV Medicine. 2009 Feb 1
• 21 citations
  Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
  Calvin J. Cohen, Daniel S Berger, Gary Blick, Howard Grossman, Dushyantha Jayaweera, P. Shalit, Melanie A. Thompson, Monika Peeters, Marie-Pierre de Béthune, Ellen Voo...> ;AIDS. 2009 Jan 28
• The biography of an HIV doctor. A 20-year retrospective.
  Daniel S Berger> ;Positively Aware. 2009 Jan 1
• Sexual encounters with undetectable HIV-positive men. A controversy about HIV transmission.
  Daniel S Berger> ;Positively Aware. 2008 Nov 1
• 44 citations
  Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
  Julian Falutz, Soraya Allas, Jean-Claude Mamputu, Diane Potvin, Donald P. Kotler, Michael Somero, Daniel S Berger, Stephen Brown, Gary Richmond, Jeffrey Fessel, Ralph ...> ;AIDS. 2008 Sep 12
• Comparing two integrase inhibitors. The first head-to-head study comparing raltegravir and elvitegravir.
  Daniel S Berger> ;Positively Aware. 2008 Sep 1
• 56 citations
  First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
  Benjamin Young, Kathleen Squires, Parul Patel, Edwin DeJesus, Nicholaos C. Bellos, Daniel S Berger, Denise H. Sutherland-Phillips, Qiming Liao, Mark S. Shaefer, Paul W...> ;AIDS. 2008 Aug 20
• 23 citations
  Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
  Richard Elion, Edwin DeJesus, Michael Sension, Daniel S Berger, William J. Towner, Gary Richmond, Marty St. Clair, Linda Yau, Belinda Ha> ;HIV Clinical Trials. 2008 May 1
• 1 citations
  Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
  Daniel S Berger> ;Positively Aware. 2008 May 1
• Join now to see all